A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 7501-7501 ◽  
Author(s):  
Karen Kelly ◽  
Nasser K. Altorki ◽  
Wilfried Ernst Erich Eberhardt ◽  
Mary E.R. O'Brien ◽  
David R. Spigel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Tumor Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
Complete Tumor Resection ◽  
Phase 3 ◽  
Double Blind ◽  
Complete Tumor

scholarly journals Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

2014 ◽  
Vol 15 (1) ◽  
pp. 59-68 ◽  
Author(s):  
Charles Butts ◽  
Mark A Socinski ◽  
Paul L Mitchell ◽  
Nick Thatcher ◽  
Libor Havel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Phase 3 ◽  
Double Blind

scholarly journals Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study

2019 ◽  
Vol 121 (5) ◽  
pp. 372-377 ◽  
Author(s):  
Harry J. M. Groen ◽  
◽  
Erik H. F. M. van der Heijden ◽  
Theo J. Klinkenberg ◽  
Bonne Biesma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Phase 3
Sign in / Sign up

Export Citation Format

Share Document